论文部分内容阅读
[目的]评价吉西他滨固定剂量率静滴联合奥沙利铂(GEMOX方案)治疗晚期胆道癌的疗效和毒副作用。[方法]47例晚期胆道癌患者均接受吉西他滨1 000mg/m2,10mg/(m2.min)静滴,d1、8;奥沙利铂130mg/m2,静脉滴注2h,d1;每3周重复。至少化疗3个周期。[结果]47例患者均可评价疗效,无完全缓解病例,部分缓解9例(19.2%),稳定22例(46.8%),进展16例(34.0%),总有效率(CR+PR)为19.2%(9/47)。中位无进展生存期(PFS)4.7个月,中位总生存期(OS)9.3个月。主要毒副反应为中性粒细胞减少、血小板减少,恶心、呕吐,肝肾和外周神经毒性等。[结论]吉西他滨固定剂量率静滴联合奥沙利铂治疗晚期胆道癌有效,但其血液学毒性需引起重视。
[Objective] To evaluate the curative effect and toxicity of gemcitabine at a fixed dose rate combined with oxaliplatin (GEMOX) in the treatment of advanced cholangiocarcinoma. [Methods] Forty-seven patients with advanced cholangiocarcinoma received Gemcitabine 1 000 mg / m2 and 10 mg / (m2.min) intravenously, d1,8, oxaliplatin 130 mg / m2, intravenous drip 2h, d1 every 3 weeks . At least 3 cycles of chemotherapy. [Result] Ninety-seven cases (19.2%) were stable, 22 cases (46.8%) were stabilized, and 16 cases (34.0%) were progressive. The total effective rate (CR + PR) 19.2% (9/47). The median progression-free survival (PFS) was 4.7 months, and the median overall survival (OS) was 9.3 months. The main side effects of neutropenia, thrombocytopenia, nausea, vomiting, liver and kidney and peripheral neurotoxicity. [Conclusion] The fixed dose rate of gemcitabine combined with oxaliplatin is effective in the treatment of advanced cholangiocarcinoma, but its hematological toxicity needs attention.